Abstract: An ear-worn electronic device comprises a housing configured to be supported by, at, in or on an ear of a wearer. Electronic circuitry is disposed in the housing and comprises a processor. A power source and a receiver or a speaker are respectively disposed in or on the housing. A microphone array is disposed in or on the housing and operatively coupled to the electronic circuitry. The microphone array comprises a plurality of microphones. The processor is configured to operate a set of two or more of the microphones in a directional mode, detect degradation in performance of any microphone of the microphone set, and switch microphone operation from the directional mode to a safe mode using at least one non-degraded microphone of the microphone set in response to detecting the microphone performance degradation.

Abstract: The invention provides processes for the manufacture of a compound of formula (IA). The invention further provides improved methods for the conversion of the compound of formula (IA) into pregabalin.

Abstract: Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

Abstract: The present invention provides methods of preparing substituted 2-(pyridin-2-ylamino)-pirido[2,3-d]pyrimidin-7-ones (formula 1), useful in treating cell proliferative disorders, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides methods of preparing substituted 2-(pyridin-2-ylamino)-pirido[2,3-d]pyrimidin-7-ones (formula 1), useful in treating cell proliferative disorders, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

Abstract: A futon having a mattress frame with a seat deck and a back deck, a front edge of the seat deck being concealed from view when the mattress frame is in a seated position. The front edge of the seat deck of the mattress frame is supported by a shelf projecting rearward from a front rail of the futon. The front rail partially defines a concealed storage compartment within the futon. The futon is provided with a hinged mattress having a first portion and a second portion hingedly connected only along an elongate corner edge of each of the first and second portions.